Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BDRX 
Biodexa Pharmaceticals (BDRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: BDRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $185.05
1 Year Target Price $185.05
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.88M USD | Price to earnings Ratio - | 1Y Target Price 185.05 |
Price to earnings Ratio - | 1Y Target Price 185.05 | ||
Volume (30-day avg) 1 | Beta 0.87 | 52 Weeks Range 5.00 - 108.90 | Updated Date 09/17/2025 |
52 Weeks Range 5.00 - 108.90 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -135.52 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.04% | Return on Equity (TTM) -61.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2596934 | Price to Sales(TTM) 0.58 |
Enterprise Value 2596934 | Price to Sales(TTM) 0.58 | ||
Enterprise Value to Revenue 4.7 | Enterprise Value to EBITDA 0.03 | Shares Outstanding 619523 | Shares Floating 60827246232 |
Shares Outstanding 619523 | Shares Floating 60827246232 | ||
Percent Insiders 0.95 | Percent Institutions 6.25 |
Upturn AI SWOT
Biodexa Pharmaceticals
Company Overview
History and Background
Biodexa Pharmaceuticals Plc, formerly known as Nucana Biomaterials, was founded in 2008. The company is focused on developing innovative medicines for unmet medical needs, particularly in oncology. It has evolved from a biomaterials focus to a pharmaceutical company.
Core Business Areas
- Oncology Drug Development: Developing drug candidates to treat cancer, with a focus on improving bioavailability and efficacy.
Leadership and Structure
Stephen Stamp is the Chief Executive Officer. The company has a board of directors overseeing strategic direction and governance.
Top Products and Market Share
Key Offerings
- MTX110: A formulation of methotrexate designed for direct administration into the central nervous system to treat central nervous system (CNS) tumors, with a focus on overcoming bioavailability challenges. No current market share available, as still in development. Competitors include standard methotrexate formulations and other chemotherapeutic agents targeting CNS tumors, such as temozolomide and cytarabine.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with a focus on developing innovative therapies. The oncology segment is particularly active, driven by significant unmet needs and increasing prevalence of cancer.
Positioning
Biodexa Pharmaceuticals is positioning itself as a developer of innovative drug formulations that improve bioavailability and efficacy, focusing on niche oncology indications.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth billions of dollars. Biodexa focuses on niche indications, so their TAM is smaller, potentially in the hundreds of millions. Their positioning involves capturing a significant share of this targeted TAM through superior drug delivery.
Upturn SWOT Analysis
Strengths
- Innovative drug delivery technology
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Small market capitalization
Opportunities
- Successful clinical trial outcomes
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
Competitors and Market Share
Key Competitors
- LLY
- MRK
- BMY
Competitive Landscape
Biodexa Pharmaceuticals faces significant competition from established pharmaceutical companies with greater resources and established market presence. Their advantage lies in their innovative drug delivery technology and focus on niche indications.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by the advancement of their drug development pipeline.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary significantly due to the speculative nature of pharmaceutical development.
Recent Initiatives: Focus on clinical trials for MTX110 and exploring partnerships.
Summary
Biodexa Pharmaceuticals is a developmental stage pharmaceutical company focused on improving drug delivery for oncology. It faces risks associated with clinical trials and competition from larger companies. However, successful clinical trials and partnerships could drive significant growth. The company's innovative approach to drug formulation presents a unique opportunity but relies on regulatory approvals and efficient use of capital.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-party financial data providers
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investing in pharmaceutical companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biodexa Pharmaceticals
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-12-07 | CEO, CFO, Company Secretary & Director Mr. Stephen Anthony Stamp | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.biodexapharma.com |
Full time employees 13 | Website https://www.biodexapharma.com | ||
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.